Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1207 vs Eylea in wet AMD
NCT05345236Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2019
- Primary completion
- Jan 2022
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of QL1207 in exudative macular degeneration, sponsored by Qilu Pharmaceutical. Started Aug 2019; status: completed.
02
Drugs
QL1207
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT05345236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345236.